A Comparison of Sucralfate Dosage Schedule in Duodenal Ulcer Healing

In, Marks; Jp, Wright; Nh, Gilinsky; Ah, Girdwood; Tobias, R; Boyd, E. J. S.; Kalvaria, I; Sj, O'Keefe; Newton, Keith; Lucke, W

doi:10.1097/00004836-198608000-00007

Cited by 24 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Healing rates after 4 weeks of sucralfate, and therapy rates ranged from 60 to 92% in duodenal ulcer patients and from 47 to 62% in gastric ulcer patients, respective ly. Single blind studies showed that sucralfate given in a dose of 2 g daily is as effective as a conventional dose of 1 g four times daily [39], These findings were also confirmed in con trolled double blind studies [49],…”

Section: Short-term Ulcer Healingmentioning

confidence: 61%

Role of Sucralfate in Peptic Disease

P²

1992

Dig Dis

View full text Add to dashboard Cite

Sucralfate, a basic aluminium salt of sucrose, was the first successful drug with a major cytoprotective mechanism of action. It binds bile acids and pepsin and adheres to both ulcerated and nonulcerated mucosa. Sucralfate stimulates the synthesis and release of gastric mucosal prostaglandins as well as bicarbonate and the epidermal growth factor which stimulates healing. Sucralfate is the safest drug available today in the treatment of dyspeptic symptoms and compared to ranitidine and cimetidine it has the following characteristics. (1) It effectively prevents mucosal damage by alcohol. (2) The short-term healing of duodenal ulcers is the same for sucralfate, cimetidine and ranitidine. (3) Sucralfate-treated patients have a lower recurrence rate of duodenal ulceration after healing when compared with cimetidine and the recurrence rate is not connected with the presence or absence of Campylobacter pylori.

show abstract

Section: Short-term Ulcer Healingmentioning

confidence: 61%

Role of Sucralfate in Peptic Disease

P²

1992

Dig Dis

View full text Add to dashboard Cite

show abstract

Identification, Diagnosis, and Treatment of Acid‐Related Diseases in the Elderly: Implications for Long‐Term Care

Garnett,

Garabedian‐Ruffalo

1997

Pharmacotherapy

View full text Add to dashboard Cite

Acid‐related disorders such as peptic ulcer disease and gastroesophageal reflux disease occur frequently in the elderly and are associated with a high frequency of morbidity and mortality. The proton pump inhibitors lansoprazole and omeprazole produce faster rates of healing and greater symptomatic relief in patients with acid‐related disorders than histamine2‐receptor antagonists, are well tolerated, and are associated with few adverse events. Compared with omeprazole, which interacts with diazepam, warfarin, and phenytoin, lansoprazole produces only a minor increase in theophylline clearance. Proton pump inhibitors in combination with antibiotic therapy can eradicate Helicobacter pylori, the main risk factor in the recurrence of peptic ulcer disease, obviating the need for maintenance therapy. Long‐term acid suppression with proton pump inhibitors may be necessary to prevent the recurrence of gastroesophageal reflux disease. The safety and efficacy profile of these agents makes them ideal for the treatment of acid‐related diseases in elderly patients. (Pharmacotherapy 1997;17(5);938–958)

show abstract

Upper Gastrointestinal Disorders

Garnett¹,

Dukes²

1992

Applied Therapeutics

View full text Add to dashboard Cite

A Comparison of Sucralfate Dosage Schedule in Duodenal Ulcer Healing

Cited by 24 publications

References 0 publications

Role of Sucralfate in Peptic Disease

Role of Sucralfate in Peptic Disease

Identification, Diagnosis, and Treatment of Acid‐Related Diseases in the Elderly: Implications for Long‐Term Care

Upper Gastrointestinal Disorders

Contact Info

Product

Resources

About